![](https://investorshub.advfn.com/uicon/334928.png?cb=1606947403)
Thursday, January 30, 2014 3:29:58 PM
Thursday, 30 January 2014 18:27 Reports about comments' content 0 Comments
.
ImmunoCellular Therapeutics, Ltd. - Product Pipeline Review - 2013
Reportstack has announced a new market research publication on ImmunoCellular Therapeutics, Ltd. - Product Pipeline Review - 2013 which provides data on the ImmunoCellular Therapeutics, Ltd.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from proprietary databases, ImmunoCellular Therapeutics, Ltd.’s corporate website, SEC filings, investor presentations and featured press releases, both from ImmunoCellular Therapeutics, Ltd. and industry-specific third party sources, put together by team of industry experts.
Scope
- ImmunoCellular Therapeutics, Ltd. - Brief ImmunoCellular Therapeutics, Ltd. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of ImmunoCellular Therapeutics, Ltd. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of ImmunoCellular Therapeutics, Ltd. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the ImmunoCellular Therapeutics, Ltd.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate ImmunoCellular Therapeutics, Ltd.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of ImmunoCellular Therapeutics, Ltd. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the ImmunoCellular Therapeutics, Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with ImmunoCellular Therapeutics, Ltd..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of ImmunoCellular Therapeutics, Ltd. and identify potential opportunities in those areas.
To view the table of contents and know more details please visit ImmunoCellular Therapeutics, Ltd. - Product Pipeline Review - 2013.
Recent IMUC News
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 08/02/2023 07:11:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM